We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial
24 Apr 2025 - Sweden, 24 April 2025 – Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical […]
Read morePolyPeptide announces results of the annual General Meeting 2025
9 Apr 2025 - Baar, 9 April 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all […]
Read moreExpanding the Reach of Sustainable Solid-Phase Peptide Synthesis
2 Apr 2025 - Alloc protecting group expanded the peptide synthesis toolbox. Its removal can sometimes be seen as an issue: toxic solvents, air-sensitive Pd0) reagents, challenging upscaling. Not anymore […]
Read moreImpurities in Peptide Drug Substance and Challenges Faced during Registration (in US, EU, Brazil and China Markets) and Commercial Phase
20 Mar 2025 - Controlling impurities in complex drug substances is a crucial part of development and due to lack of harmonized approaches from Health authorities, the manufacturer faces many […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2025
18 Mar 2025 - Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth […]
Read morePolyPeptide with substantial improvements in profitability and cash flow, positioned for strong growth
11 Mar 2025 - Baar, 11 March 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its annual results for 2024 […]
Read moreCytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs
13 Jan 2025 - This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that address […]
Read moreDoubling of production capacity at the manufacturing site in Malmö
8 Jan 2025 - Baar, 8 January 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the planned doubling of solid-phase peptide […]
Read moreLarge-scale SPPS capacity in Braine-l’Alleud starts production
16 Dec 2024 - Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the start of production with the […]
Read more